Publikasi Scopus FKUI 2021 per tanggal 30 September 2021 (661 artikel)

Yunihastuti E., Amelia F., Hapsari A.I., Wicaksana B., Natali V., Widhani A., Sulaiman A.S., Karjadi T.H.
8850357600;57216937074;57224070662;57216937319;57216936185;57202561455;57216938482;57219422563;
Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus
2021
Health and Quality of Life Outcomes
19
1
154
Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Ciptomangunkusumo Hospital, Diponegoro 71, Jakarta, Indonesia; HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Hepatobilliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Yunihastuti, E., Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Ciptomangunkusumo Hospital, Diponegoro 71, Jakarta, Indonesia, HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Amelia, F., HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Hapsari, A.I., HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Wicaksana, B., HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Natali, V., HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Widhani, A., Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Ciptomangunkusumo Hospital, Diponegoro 71, Jakarta, Indonesia, HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia; Sulaiman, A.S., Hepatobilliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Karjadi, T.H., Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Ciptomangunkusumo Hospital, Diponegoro 71, Jakarta, Indonesia, HIV Integrated Services, Ciptomangunkusumo Hospital, Jakarta, Indonesia
Background: We conducted a real-life study of health-related quality of life (HRQoL) transformation before and 12 weeks after sofosbuvir and daclatasvir therapy in HCV/HIV co-infected patients. Factors related to the significant changes of each HRQoL domain/item were also evaluated. Methods: A prospective study was performed in the HIV integrated clinic at Cipto Mangunkusumo Hospital, Jakarta. HCV/HIV co-infected patients who started sofosbuvir and daclatasvir from government free DAA program in 2017–2019. WHOQoL-HIV BREF and RAND SF-36 questionnaires were recorded at baseline and post-treatment week 12. Results: 145 patients with mean age of 37.8 years (SD = 4.2) were included in the analysis. Most of patients were male (89%), previous IVDU (89%), active smoker (50.4%) and non-cirrhosis (80%). SVR12 was achieved in 95.5% of patients. Sofosbuvir and daclatasvir treatments showed positive impacts on 2 domains and 2 other items of WHOQoL-HIV BREF and 2 domains and 1 item of SF-36. Predicting factors of significant increase in each domain/item were: male and normal body mass index (BMI) for level of independence (RR 4.01,95% CI 1.09–14.74 and 4.80,95% CI 1.79–12.81); higher HCV-RNA for overall perception of QoL (RR 0.42,95% CI 0.18–0.94); non-smoking status for overall perception of health (RR 0.32,95% CI 0.15–0.66); male and fibrosis stage 0–1 for general health (RR 6.21,95% CI 1.69–22.88 and 2.86,95% CI 1.16–7.00); and the use of NNRTI-based ART (RR 5.23, 95% CI 1.16–23.65). Spiritual/personal belief decline was predicted by non-smoking status (RR 0.46, 95% CI 0.23–0.95). Treatment success was not associated with any changes of HR-QoL domain/item. Conclusions: HCV/HIV co-infected patients were successfully treated with sofosbuvir and daclatasvir and experienced improvement of HRQoL 12 weeks after treatment completion. © 2021, The Author(s).
Daclastavir; HCV; Health-related quality of life; Hepatitis C; HIV; Sofosbuvir
antivirus agent; carbamic acid derivative; imidazole derivative; pyrrolidine derivative; sofosbuvir; valine; adult; chronic hepatitis C; combination drug therapy; comparative study; complication; female; human; Human immunodeficiency virus infection; Indonesia; male; mixed infection; prospective study; psychology; quality of life; treatment outcome; Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Indonesia; Male; Prospective Studies; Pyrrolidines; Quality of Life; Sofosbuvir; Treatment Outcome; Valine
BioMed Central Ltd
14777525
34039353
Article
Q1
1084
3877